Journal profile · Hematology
Critical Reviews in Oncology/Hematology
ISSN 1040-8428 · eISSN 1879-0461 · Elsevier Ireland Ltd · UNITED STATES · Monthly · Founded 1983
Critical Reviews in Oncology/Hematology: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 6.19; hybrid open access; APC about USD 4,190; median 87 days to acceptance (131 articles, last 24 months); community-reported acceptance: moderate (Elsevier website: 83%); 417 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Critical Reviews in Oncology/Hematology is published by Elsevier Ireland Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Diverse Scientific and Economic Studies, together about 19.7% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world.The journal considers articles on the following themes:Basic Experimental OncologyCareer Development and Education in OncologyClinical ResearchHematologyImmunotherapyMolecular Pathology, Genomics and omics, and Liquid BiopsyPalliative SupportPediatric OncologyRadiotherapyRegulatory, Ethics, and Health PolicySolid TumorsStatistics, Meta-analysis, and Clinical Trial DesignSurgeryCritical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy (ISLB).All review articles, invited or submitted spontaneously, are subject to peer review before final acceptance. Further information regarding the submission of manuscripts and guidelines for the preparation of the manuscripts can be found in the Guide for Authors.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Christian RolfoPublisher website
Editorial board by country: none in mainland China; most named United States 24, Italy 21, Switzerland 10, Canada 7, France 6 (95 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine7.2%
- Lung Cancer Treatments and MutationsMedicine6.4%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance6.2%
- Human auditory perception and evaluationEngineering6%
- Educational Robotics and EngineeringComputer Science6%
- Colorectal Cancer Treatments and StudiesMedicine5.2%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology4.8%
- Lymphoma Diagnosis and TreatmentMedicine4.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
| Minor | Hematology | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Hematology | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.19LetPub ·
- Impact factor (publisher)
- 6.2Publisher website ·
- CiteScore 2026-06
- 9.5LetPub ·
- CiteScore (publisher)
- 9.5Publisher website ·
- SJR 2026-06
- 1.98LetPub ·
- SNIP 2026-06
- 1.54LetPub ·
- h-index
- 111LetPub ·
- h-index
- 182OpenAlex ·
- i10-index
- 3,394OpenAlex ·
- 2-year mean citedness
- 5.86OpenAlex ·
- Self-citation rate
- 1.6%LetPub ·
- Share of gold OA articles
- 31.46%LetPub ·
Volume
- Articles per year
- 385LetPub ·
Articles by year OpenAlex count · 6,057 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 436 | 135 | 413 |
| 2025 | 417 | 134 | 2,691 |
| 2024 | 280 | 123 | 3,534 |
| 2023 | 212 | 88 | 3,511 |
| 2022 | 211 | 80 | 5,918 |
| 2021 | 246 | 75 | 6,672 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
87 daysMedian, submission to acceptance · P25–P75 52 days – 150 days
- Acceptance to online
- median 3 days (131 articles)
- Submission to online
- median 89 days
- Sample
- 131 articles with submission and acceptance dates (936 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- 83%LetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- First decision after review
- 27 daysPublisher website ·
- Submission to acceptance
- 69 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,190 / EUR 3,920 / GBP 3,350 / JPY 519,690 | — | — | |
| Publisher website | USD 4,440 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare10 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 8,000 words
- Reference style
- Author–date
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Required
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
- Not considered
- case report
Article types accepted3, with length limits
- perspectiveCritical Reviews in Oncology/Hematology is dedicated to the publication of reviews that offer a clear perspective on its topic, with an up-to-date and innovativ…Length not stated
- reviewCritical Reviews in Oncology/Hematology is dedicated to the publication of reviews that offer a clear perspective on its topic, with an up-to-date and innovativ…main text ≤ 8,000 words
- review articleCritical Reviews in Oncology/Hematology is dedicated to the publication of reviews that offer a clear perspective on its topic, with an up-to-date and innovativ…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Double anonymized peer review Model summary
This journal follows a double anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Ireland Ltd
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1983
- ISSN
- 1040-8428
- Electronic ISSN
- 1879-0461
- Society / sponsor
- European School of Oncology
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Critical Reviews in Oncology/Hematology
What CAS zone is Critical Reviews in Oncology/Hematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Critical Reviews in Oncology/Hematology is in Zone 2 of Medicine, and in Zone 2 of the minor category Hematology / Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Critical Reviews in Oncology/Hematology?
The latest impact factor listed by LetPub is 6.19; CiteScore 9.5, h-index 182.
How long does peer review take at Critical Reviews in Oncology/Hematology?
Based on the dates recorded on 131 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 87 days (interquartile range 52–150 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Moderate (Elsevier website: 83%)”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Critical Reviews in Oncology/Hematology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 8,000 words; Reference style: Author–date; First submission: Free format: the journal's layout is not required; Suggested reviewers: Required; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Critical Reviews in Oncology/Hematology based?
Of the 95 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (24), Italy (21) and Switzerland (10). Counted from the institutions listed on the board page; for reference only.
Which databases index Critical Reviews in Oncology/Hematology?
According to LetPub and DOAJ records, Critical Reviews in Oncology/Hematology is indexed in SCIE and Scopus.
Is Critical Reviews in Oncology/Hematology open access, and what is the APC?
Critical Reviews in Oncology/Hematology is a hybrid journal. For open-access publication: APC about USD 4,190.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .